证券代码：002900 证券简称：哈三联 公告编号：2025-037 哈尔滨三联药业股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 二、担保进展情况 1、近日，公司与中信银行股份有限公司（哈尔滨分行）（以下简称"中信银 行"） 签订了编号为"【2025 信银哈最高额保证合同（线下版）（3.0 版，2023 年） 字第 105401 号】"的《最高额保证合同》，同意为"兰西制药"与中信银行在一 定期限内连续发生的多笔债务的履行提供最高额保证担保，所担保债权之最高额 限度为债权本金人民币壹仟万元整和相应的利息、罚息、复利、违约金、损害赔 偿金、迟延履行期间的债务利息、迟延履行金及为实现债权、担保权利等所发生 的一切费用（包括但不限于诉讼费、仲裁费、律师费、差旅费、评估费、过户费、 保全费、公告费、公证认证费、翻译费、执行费、保全保险费等）和其他所有应 付的费用之和。 2、近日，公司与兴业银行股份有限公司（哈尔滨分行）（以下简称"兴业银 行"） 签订了编号为"202556216 保证 2002 号"的《最高额保证合同 ...

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. plans to expand its business scope to include the production of plastic packaging containers for food, following the approval of the board of directors and pending shareholder approval [1][5]. Business Scope Change - The company's previous business scope included various pharmaceutical and healthcare-related activities such as drug production, wholesale, retail, and medical device manufacturing [2][4]. - The new business scope will add "production of plastic packaging containers for food" to its existing operations, which encompass drug production, cosmetics production, food production, and medical device manufacturing [2][4]. Company Charter Revision - The company has revised its charter to reflect the changes in its business scope, ensuring that the new activities are officially documented [3][5]. - The charter revision maintains all other provisions unchanged, and the board has requested authorization from the shareholders to handle subsequent business registration procedures [5].

证券代码：002900 证券简称：哈三联 公告编号：2025-035 哈尔滨三联药业股份有限公司 1 具体经营项目以相关部门批准文件或许可证件为准） 变更后经营范围：经依法登记，公司的经营范围是：许可项目：药品生产； 药品批发；药品零售；药品委托生产；药品进出口；化妆品生产；食品生产；饮 料生产；食品销售；食品互联网销售；保健食品生产；第二类医疗器械生产；第 三类医疗器械生产；第三类医疗器械经营；消毒剂生产（不含危险化学品）；消 毒器械生产；消毒器械销售；卫生用品和一次性使用医疗用品生产；道路货物运 输（不含危险货物）；检验检测服务；食品用塑料包装容器工具制品生产。 一般项目：医用包装材料制造；第一类医疗器械生产；第一类医疗器械销售； 第二类医疗器械销售；食品销售（仅销售预包装食品）；食品互联网销售（仅销 售预包装食品）；保健食品（预包装）销售；互联网销售（除销售需要许可的商 品）；化妆品批发；化妆品零售；卫生用品和一次性使用医疗用品销售；消毒剂 销售（不含危险化学品）；医学研究和试验发展；生物化工产品技术研发；技术 服务、技术开发、技术咨询、技术交流、技术转让、技术推广；非居住房地产租 赁；住房租赁。（依法 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-036 哈尔滨三联药业股份有限公司 关于召开 2025 年第一次临时股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会第二十二次 会议审议通过了《关于召开2025年第一次临时股东大会的议案》，现就本次股东 大会的相关事宜通知如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会。 2、股东大会的召集人：公司第四届董事会。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件、《上市公司股东大会规则》和《公司章程》的规定。 4、会议召开的日期、时间： 1）现场会议召开时间：2025 年 7 月 11 日 16:00； 2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 7 月 11 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 7 月 11 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-034 哈尔滨三联药业股份有限公司 第四届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会第二十 二次会议（以下简称"本次会议"）通知以电子邮件及微信方式于 2025 年 6 月 25 日发出。 2、本次会议于 2025 年 6 月 25 日以通讯表决的方式召开。 3、本次会议应到董事 9 名，实际出席并表决的董事 9 名。 4、公司董事长秦剑飞先生主持了会议，公司监事及总裁列席。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、董事会会议审议情况 全体董事一致同意豁免本次会议提前 2 日通知的时限要求，同意于 2025 年 6 月 25 日召开本次会议。 表决情况：有效表决 9 票，同意 9 票，反对 0 票，弃权 0 票。 表决结果：通过。 2、审议通过《关于变更公司经营范围及 ...

Core Viewpoint - The meeting emphasized the importance of the "Promotion Law of Private Economy" as a foundational law for the development of the private economy in China, reflecting the government's commitment to supporting private enterprises and ensuring their sustainable growth [2]. Group 1: Policy and Government Support - The Harbin Municipal Government is committed to implementing policies that promote the development of the private economy, viewing it as a key driver for economic growth and industrial upgrading [2]. - The government aims to treat all types of enterprises equally, fostering a healthy environment for private economic development [2]. - The Harbin Development and Reform Commission has established a mechanism for ongoing communication with private enterprises to address their concerns and improve the business environment [2][3]. Group 2: Business Engagement and Feedback - A total of 12 private enterprises participated in the recent meeting, providing feedback on issues such as financing support, market expansion, and industrial collaboration [1]. - The Harbin Development and Reform Commission has organized six sessions of private enterprise meetings this year, involving 64 private companies and 10 financial institutions to gather insights on various business needs [3]. - The commission has developed a structured approach to address common issues raised by enterprises, including a feedback mechanism to ensure that all concerns are acknowledged and addressed in a timely manner [3].

Core Viewpoint - The announcement details the share reduction plans of key executives at Harbin Sanlian Pharmaceutical Co., Ltd., including specific timelines and the number of shares to be sold [1][2][3]. Group 1: Shareholders' Information - The shareholders planning to reduce their holdings include Liang Yanfei (Vice President and Secretary of the Board), Zhu Zihong (Director), and Zhao Zhicheng (CFO) [1]. - As of the announcement date, the shareholding situation of the shareholders is as follows: Liang Yanfei holds 808,800 shares (0.2557% of total shares), Zhu Zihong holds 100,000 shares (0.0316%), and Zhao Zhicheng also holds 100,000 shares (0.0316%) [1]. Group 2: Reduction Plan Details - Liang Yanfei plans to reduce his holdings by up to 202,200 shares (25% of his holdings), which represents 0.0639% of the company's total shares [3]. - Zhu Zihong and Zhao Zhicheng each plan to reduce their holdings by 25,000 shares (25% of their holdings), which is 0.0079% of the company's total shares [3]. - The reduction period is set from July 7, 2025, to October 6, 2025, with a stipulation that no shares will be sold during the window period [1][3]. Group 3: Compliance and Commitments - Liang Yanfei has adhered to the commitments made in the company's IPO prospectus regarding share transfers, which include restrictions on the number of shares that can be sold within specific time frames [2][4]. - The reduction plan is consistent with previously disclosed commitments by the shareholders, ensuring compliance with relevant regulations [4].

Group 1 - The company Harsan (002900) announced that its director, vice president, and board secretary Liang Yanfei plans to reduce his holdings by no more than 202,200 shares, accounting for 0.0639% of the total share capital [1] - Director Zhu Zihong plans to reduce his holdings by no more than 25,000 shares, representing 0.0079% of the total share capital [1] - Chief Financial Officer Zhao Zhicheng also plans to reduce his holdings by no more than 25,000 shares, which is 0.0079% of the total share capital [1] Group 2 - The reason for the share reduction is personal financial needs [1] - The method of reduction will be through centralized bidding transactions [1] - The reduction period is set for three months starting from 15 trading days after the announcement date [1]

证券代码：002900 证券简称：哈三联 公告编号：2025-033 哈尔滨三联药业股份有限公司 关于董事、高级管理人员减持股份的预披露公告 董事、副总裁、董事会秘书梁延飞先生，董事朱自红先生、财务总监赵志成 先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有哈尔滨三联药业股份有限公司（以下简称"公司"或"本公司"）股份 808,800股（占本公司总股本比例0.2557%）的董事、副总裁、董事会秘书梁延飞 先生计划在自本减持计划公告之日起15个交易日后的3个月内（即2025年7月7日 -2025年10月6日，且窗口期不减持），以集中竞价方式减持本公司股份不超过 202,200股（占本公司总股本比例0.0639%）。 2、持有本公司股份100,000股（占本公司总股本比例0.0316%）的董事朱自 红先生计划在自本减持计划公告之日起15个交易日后的3个月内（即2025年7月7 日-2025年10月6日，且窗口期不减持），以集中竞价方式减持本公司股份不超过 25,000股（占本公司总股本比 ...

Group 1 - The A-share chemical pharmaceutical sector is experiencing a volatile correction, with companies such as Haichen Pharmaceutical and Yong'an Pharmaceutical both declining over 9% [1] - Other companies including Yipinhong, Hasanlian, Tonghua Jinma, Hanyu Pharmaceutical, and Hehua Co. have also seen declines of around 5% [1]